FASTINOV announced its participation in the 34th European Congress of Clinical Microbiology and Infectious Diseases in Barcelona. The 2024 programme offered an opportunity to discuss real-world hospital use, customer evaluations and scientific evidence around ultra-rapid AST.
Presenting the next stage of development
The company’s presence focused on how rapid susceptibility testing can move beyond proof of concept and become part of a practical laboratory workflow. FASTINOV shared its progress with professionals involved in clinical microbiology, infectious diseases and antimicrobial stewardship.
Evidence and collaboration
The congress also enabled discussions with hospitals, distributors and strategic partners. These conversations were important for understanding the operational requirements of laboratories evaluating new approaches to same-shift susceptibility reporting.
At ECCMID 2024, FASTINOV presented its technology in the context of hospital implementation, customer evaluation and ongoing scientific collaboration.